Purpose. To analyse the species distribution and the susceptibility profiles to the major antifungal agents of Candida isolated from bloodstream infections (BSIs) in both intensive care units (ICUs) and non-ICU wards in a tertiary care hospital in Italy from 2010 until 2015.
INTRODUCTION
Candida is an important cause of bloodstream infections (BSIs), causing significant mortality and morbidity in healthcare settings. The growing incidence of candidamia has been reported in high-impact studies conducted at a global level and the overall incidence has risen fivefold in recent decades [1, 2] . Candida spp. have been reported to be between the fourth and the sixth most common nosocomial bloodstream isolates in American and European studies [3, 4] . However, the species distribution and the susceptibility profiles detected in the various hospitals evidenced discrepancies at the local level, with peculiarities among the hospitalization wards [5] . Indeed, patients hospitalized in intensive care units (ICUs) are generally considered to be at high risk of developing candidaemia, even though a generally increased incidence has been observed in other hospital wards [6, 7] . Treatment of candidaemia mainly consists of the application of antifungal agents such as fluconazole, amphotericin B and, more recently, echinocandins. However, the widespread use of antifungal agents in the prophylaxis or empirical treatment of invasive mycoses has led to changes in the epidemiology and susceptibility of these yeasts [8, 9] . In fact, recent studies highlighted the emergence of strains that are resistant to azoles and echinocandins [10] , which might represent a major challenge for prophylactic and therapeutic approaches. Therefore, continuous surveillance studies at the local level are mandatory.
agents of Candida isolated from BSIs in both ICU and non-ICU wards, such as general medicine and surgery wards, in a tertiary care academic hospital in central Italy over a 6-year period (2010) (2011) (2012) (2013) (2014) (2015) . Data are provided for a progressively enhanced incidence of BSI sustained by Candida, and for variations in the species distribution and susceptibility profiles, with a relatively high impact of C. parapsilosis complex (including C. parapsilosis sensu stricto, C. ortho psilosis and C. metapsilosis) being seen during the observation period.
METHODS
Design, setting and study population Episodes of BSIs involving Candida were recorded in non-onco-haematological patients from January 2010 till December 2015 in a retrospective single-centre observational cohort study. The patients were hospitalized in the ICUs (including neonatal, paediatric, surgery, neurosurgery, cardiac surgery, anaesthesia, transplant and trauma unit ICUs), medical and surgery wards of a 1300-bed multiple-building tertiary-care university hospital with an average admission of 38 000 patients/year (Policlinico Umberto I of Rome, Italy). In the infective episodes under consideration Candida spp. were cultured from either blood or intravascular devices (IVDs), such as central venous catheter tips, from patients meeting the criteria for nosocomial bloodstream infection due to Candida spp. [11] . Only a single strain of Candida was collected in each patient, and this was considered to be representative of an infectious episode if one or more blood or IVD cultures yielded growth of the same Candida spp. Candidaemia was defined as being IVD-associated according to microbiological criteria, i.e. when the cultures of both the catheter tip and the blood derived from a peripheral vein yielded the growth of the same species of Candida with an identical antifungal profile. Candidaemia sustained by two or more species in the same patient was defined as coinfection, and the isolation of a new species 7 days after the last positive blood culture was defined as a new infection. The cultivation of the same species of Candida with an identical susceptibility profile 30 days after the last positive culture was defined as a late recurrent (LR) infection [12] . Written consent was not required because of the observational nature of this study. This study did not involve patients or analyse interventional clinical trials, it did not involve observational studies on drugs and nor did it drive drug choices. The blood samples and IVDs were drawn by healthcare professionals at the hospitalization site of the patients and sent to the laboratory for analysis, and therefore the authors did not collect clinical samples. The patient characteristics were collected from an electronic database. These records and information were anonymized by laboratory staff members who were not involved in the study. According to the Institutional guidelines the study did not require the authorization of the Ethics Committee.
Microbiological methods
The blood samples were drawn and inoculated in Bactec Mycosis IC/F or Bactec Plus aerobic broth and incubated in the automated culture system, Bactec 9420 (Becton Dickinson, Inc., Sparks, MD, USA). Positive samples were then inoculated on Sabouraud dextrose agar supplemented with chloramphenicol (Oxoid spa, Milan, Italy) and cultured for at least 24 h at 37 C. IVDs were microbiologically examined within 15 min after the removal of the device according to the quantitative culture method of Cleri et al. [13] , with slight modifications. In brief, approximately 5 cm of the distal part of the device was placed in 1 ml of BHI broth (Biolife Italiana s.r.l., Milan, Italy) and vigorously shaken on a vortex for 30 s. A total of 10 µl of the suspension was then streaked on agar plates. After incubation at 37 C for 24 h, any growth of yeasts from both blood and IVDs was then identified by both the API ID 32C system (Biomerieux Diagnostic System, Inc., St. Louis, MI, USA), and by the MALDI-TOF technique (Bruker Daltonik GmbH, Bremen, Germany), accepting score values !1.8 [14, 15] .
The susceptibility of the yeasts to antifungal drugs (amphotericin B, AMB; posaconazole, POS; fluconazole, FLU; voriconazole, VOR; itraconazole, ITR; 5-flucytosine, 5-FC; micafungin, MIF; anidulafungin, ANI; caspofungin, CAS) was tested using the Sensititre Yeast One 10 (Trek Diagnostic Systems, East Grinstead, West Sussex, UK). The MIC values were determined, following the manufacturer's instructions, as the lowest concentration of the drug that caused a growth inhibition as revealed by the colour changes of the media. The interpretative antifungal MIC breakpoints were the species-specific clinical breakpoints (CBPs) devised by the CLSI or, in the absence of CBPs, the epidemiological cut-off values (ECVs) for antifungal agents [16] .
Statistical analysis
The incidence rate was calculated as the ratio between the number of new cases reported in the wards and the total number of patients hospitalized in the same ward each year, and this was expressed as the number of episodes/1000 admissions. The chi-square ( 2 ) test was used to determine the tendency during the observation period. A one-way ANOVA test was used to evaluate the differences between groups other than 2. Univariate analysis was based on the 2 test, or Fisher's exact test when it was needed for discrete variables. An a error <0.05 was accepted. Data were analysed using STATA statistical software (version 11.0; College Station, Tx, USA).
RESULTS
Incidence of isolation and species distribution A total of 514 non-replicative infective episodes due to Candida spp. (275 identified from the blood, 141 from IVDs, and 98 from both IVDs and blood in the IVD-associated candidaemias) were recorded from January 2010 to December 2015. The patients' (n=452) average age was 62.20 ±20.68 years and 58.41 % were male. The mean incidence of BSIs involving Candida spp. over the 6 years was 2.52 episodes/1000 admissions. The incidence ranged from 1.42 episodes/1000 admissions in 2010 to 3.63 episodes/1000 admissions in 2015, with a significantly increased trend (P<0.04) throughout the study period Fig. 1(a) . Analysis of the relative impact of isolation in the different wards showed that the incidence of BSIs in the ICU was significantly higher than that observed in the non-ICU areas, such as the surgical and medical wards ( 2 =30.6; P<0.001) (Fig. 1b) . Candida isolation from the blood presented a quite stable trend in the ICU and surgical wards, while it peaked in 2014-2015 in the medical areas (Fig. 2a, b) . A similar behaviour was observed for the IVD-related episodes in medical and ICU wards during 2014 and 2015 respectively, while a more stable trend was observed in the incidence of isolation from both the blood and IVDs in surgical wards Fig. 2 (a, b) . Analysis of the data collected during the study period showed that C. albicans and C. parapsilosis complex were the species most frequently isolated from BSIs (45.35 and 35.27 %, respectively), accounting between them for 80.62 % of all the isolates. C. glabrata and C. tropicalis were isolated in 8.9 and 6.97 % of the BSIs, making them rank third and fourth, respectively. Furthermore, the isolation rate for C. parapsilosis complex in the ICU ward was greater than that for C. albicans (42 vs 40 %) (Fig. 3a) . The impact of neonatal candidaemia was limited to eight cases in 6 years, and all of these involved C. parapsilosis complex, including three IVD-related candidaemias. Interestingly, the isolation frequency for C. parapsilosis complex presented a statistically significant (P=0.04) increased trend during the study period (Fig. 3b) . Considered in toto, the isolation of the species C. famata, C. lusitaniae, C. krusei, C. sake, C. pelliculosa, C. guillermondii and C. norvegensis presented a statistically significant (P=0.03) increased trend of isolation over the study period (Fig. 3b) .
IVD-associated candidaemia
Ninety-eight patients with an average age of 57.20 ±21.5 years, 57.14 % male, presented the growth of the same species from both the blood and IVD cultures, thus indicating that 19 % (98/514) of the infective episodes were IVDassociated. The highest incidence was observed in the ICU (6.85 episodes/1000 admissions), followed by the surgical and medical wards (0.29 and 0.1 episodes/1000 admissions, respectively). The most frequently isolated species was C. parapsilosis complex (42.85 %), and this was mainly cultured in the ICU and surgical wards (Fig. 4) , with an increasing trend of isolation during the study period (ranging from 18.2 % in 2010 through to the peak value of 71.4 % in 2014). C. albicans (overall frequency of 34.7 %) was mainly cultured in the surgical wards. Of note was the fact that patients with C. albicans in the blood presented a lower relative risk (RR: 0.57; 2 =5.05; P=0.02) of being IVDassociated.
Late recurrent infections, new infections and coinfections
Overall analysis of the data evidenced that the same Candida species with the same susceptibility profile was isolated >30 days after the first isolation in 37 patients, presenting a total of 43 episodes of candidaemia, including six patients who suffered repeated episodes from 1 to 3 months after the first isolation. The probable focus of infection in the whole group of patients with late recurrent infection resided in prolonged vascular catheterization (15 patients), urinary infection (7 patients), and either abdominal or surgical wound infection (4 patients), while for 11 patients the origin was unknown, even though 4 patients had a concomitant pulmonary colonization. C. parapsilosis complex was the species most involved in these late recurrent infections, accounting for 16 episodes in 16 patients, followed by C. albicans with 13 episodes in 12 patients, and C. glabrata with 9 episodes in 6 patients (Fig. 5 ).
Isolation of a new species 7 days after the last positive culture was observed in 28 patients (Table 1) . Once again, C. parapsilosis complex was the species most frequently involved in these new infections, being responsible for 11 new episodes in 11 patients previously infected by C. albicans, and for 5 new infections in 5 patients who had suffered from C. glabrata candidaemia. Interestingly, new species of Candida were only isolated in two patients previously infected by C. parapsilosis complex.
Coinfections were quite sporadic, being observed in 10 out of 456 patients over a 6-year period (Table 1) . However, C. parapsilosis complex was also the most frequently involved species in this case, being concomitantly isolated in five patients with C. albicans candidaemia and three patients with C. glabrata candidaemia.
MIC values of Candida isolates
The susceptibility of the Candida isolates to the antifungal drugs was tested by means of the Yeast-One system. The interpretive results were expressed through the species-specific CBPs or, in the absence of CBPs, with the ECV values ( Table 2) . Concerning the ECVs, all the tested strains were wild-type (WT) for amphotericin B, with MIC 50 and MIC 90 values ranging between 0.12 and 1 µg ml
À1
. Instead, non-WT strains were observed for flucytosine, itraconazole, posaconazole and voriconazole (C. glabrata). Peak values (13.16 %) for the non-WT strains for posaconazole were observed for C. tropicalis. For the above-mentioned drugs, the MIC 50 and the MIC 90 ranged between 0.03 and 2 µg ml
. Data relative to the CBPs showed that resistance to fluconazole was observed in 15 strains of C. parapsilosis complex (8.56 %), with 7 strains (3.74 %) showing dose-dependent susceptibility, and to a lesser extent, in 4 resistant strains of C. albicans (1.94 %). Furthermore, as expected, 6.52 % of the strains of C. glabrata were resistant to fluconazole and 93.48 % showed dosedependent susceptibility. Voriconazole was shown to be active against the majority of the isolates tested (95.37 %), with both intermediate and resistant strains mainly recorded for C. albicans and C. parapsilosis complex (6 and 11 strains, respectively). Resistance to echinocandins was evidenced for C. glabrata, with 8.89 % of the strains being resistant to caspofungin, 7.32 % being resistant to anidulafungin and 7.32 % of the strains being resistant to micafungin. Furthermore, 7.89 % of the strains of C. tropicalis displayed resistance to micafungin, and 5.41 % showed it to anidulafungin. Moreover, even though only one strain was found to be resistant to anidulafungin while showing intermediate susceptibility to micafungin, the MIC 50 s of C. parapsilosis complex for echinocandins were significantly enhanced as compared to the MIC 50 s for the same drugs of C. albicans, C. glabrata and C. tropicalis ( 2 =20.55; P<0.001) (Fig. 6a) . Differences in the susceptibility to the antifungal drugs from 2010 to 2015 were also measured. The only significant variation observed was for the MIC 50 of C. albicans to amphotericin B, which steadily increased (P<0.03) over time, even though all the strains were still in the susceptibility range (Fig. 6b) . The majority (45 %) of the isolates with MIC 50 !0.25 µg ml À1 were isolated from the internal medicine wards.
DISCUSSION
The epidemiology of candidaemia has been studied extensively worldwide, mainly in the United States, Europe and South America [17] [18] [19] [20] . In this paper we reported data concerning BSIs involving Candida spp. in the past 6 years in the metropolitan area of Rome, Italy. Our data showed a continuous and significantly increased trend of the incidence of candidaemia (from 1.42 episodes/1000 admissions in 2010 to 3.63 episodes/1000 admissions in 2015), with a mean incidence in the 6 years of 2.52 episodes/1000 admissions. In a recent survey conducted in northern Italy, Bassetti et al. [19] reported a stable, yet lower, trend of candidaemias (mean incidence of 0.79 episodes/1000 admissions). Therefore, candidaemia trends might vary depending on the geographical setting of the hospital. To stress this observation, our data were found to be comparable to those recorded in another 1500-bed hospital in Rome in the period 2008-2010 (2.53 episodes/1000 admissions) [5] , even though we did not consider onco-haematologically derived episodes. Accordingly to the literature, candidaemia episodes were mainly recorded in males aged 61-80 years (51.54 %) [5, 18, 19] . In agreement with Marchetti et al. [21] , we observed a higher prevalence of BSI episodes in the ICU, followed by non-ICU wards such as the medical and surgical wards. Furthermore, we observed that the highest incidence of the isolation of Candida spp. from IVDs was found in the ICU, with a steady-state increased trend during the study period. Other studies reported similar results [5, 19] , even though they were not fully comparable to ours, since the data were reported as a percentage and not expressed as episodes/admission in the different wards. Furthermore, we observed a striking increase in candidaemia among medical patients. These results were confirmed by recent studies performed in both central Italy [22] and Israel Table 1 . Number of episodes of reinfection and coinfection observed during the study period First and second isolate is reported for the chronology of the isolation. Other species included: C. famata, C. lusitaniae, C. krusei, C. sake, C. pelliculosa, C. guillermondii and C. norvegensis.
Candida species Reinfections Coinfections
First isolate Second isolate C. albicans C. glabrata 5 0
C. albicans C. parapsilosis 11 5
C. albicans C. tropicalis 3 1
C. glabrata C. parapsilosis 5 3
C. glabrata C. tropicalis 1 0
C. glabrata
Other species 1 0
C. parapsilosis C. tropicalis 1 0
C. parapsilosis Other pecies 1 1 Table 2 . In vitro susceptibility of yeast BSI isolates tested against nine antifungals, determined using the Sensititre YeastOne 10 method [23] , in which the authors confirmed the high incidence of candidaemia and related mortality in the internal medicine wards. In the absence of specific data in our study, we can agree with the above-mentioned authors and speculate that patients hospitalized in internal medicine wards are mainly at high risk of developing candidaemia due to higher exposure to antibiotics in the 90 days before the onset of candidaemia, or because of the relatively high incidence of failure to offer adequate and timely effective antifungal therapy. In our study we found that the most frequently isolated species were C. albicans and C. parapsilosis complex (45.35 vs 35.27 %), with a significantly enhanced trend of isolation for the latter species. These data partly agree with those of other studies, in which C. albicans was the species most frequently isolated in the bloodstream in Europe and more specifically Italy (50 %) [5] . On the other hand, the incidence of C. parapsilosis complex was reported to range between 14 and 23 % [18, 19] . In recent years very few data have been available concerning the significantly enhanced trend for isolation of C. parapsilosis complex as a causative agent for candidaemia [24] . A recent observational study conducted in the centre of Italy showed that during the years 2010-2014, C. parapsilosis complex had a high incidence rate of isolation, and that the hospitalization in the ICU was independently associated with a significantly higher risk of mortality [7] . Unfortunately, no data are available concerning the relative risk of mortality associated with candidaemia. However, C. parapsilosis complex had a higher isolation rate than C. albicans in the ICU settings of our hospital settings. Delfino et al. [25] showed that some C. parapsilosis genotypes recovered from the hands of healthcare workers were also found in blood samples. It could be that the high number of BSIs caused by C. parapsilosis complex might be, at least in part, attributable to the horizontal transmission of this species by hospital staff. Furthermore, C. parapsilosis complex can produce virulence factors, such as biofilms, especially in the presence of IVDs [26, 27] . Indeed, in our study C. parapsilosis complex was the species most frequently isolated in IVD-related candidaemia, both in the ICU and in the surgical wards, and the relationship with the biofilm production of these strains was investigated very recently [28] . Therefore, despite the fact that C. parapsilosis complex has long been considered to be a low-virulence species [29] , our observation that C. parapsilosis complex was the main species involved in IVD-related candidaemias, late recurrent infections, new infections and coinfections indicated that the pathogenic role of this species should be carefully reconsidered. Surprisingly, we observed that by comparing the incidence of isolation of the IVD-related BSI causative yeasts with the general incidence of the species isolated in both the blood and in the IVD, our study showed that the isolation of C. albicans in the blood is associated with a lower relative risk of being IVD-associated. (RR: 0.57; 2 =5.05; P=0.02). To the best of our knowledge, no other sound studies have shown this. These data should be interpreted with caution, since we cannot be sure that all the IVDs that were removed were sent for culture, or that antifungal therapy was started before they were cultured. Our Table 2 . cont. data on antifungal susceptibility showed that almost all the strains were WT for amphotericin B, even though the MIC 50 for C. albicans measured from 2010 to 2015 increased significantly (P<0.03), and the majority of these strains were isolated from the internal medicine wards. In the absence of data concerning drug consumption we can only stress the above-mentioned hypothesis [23] of there being a high incidence of inadequate antifungal therapy in medical wards. According to a recently published report [30] , most of the strains in our study were susceptible to echinocandins, even though, as compared to other species, C. parapsilosis complex showed a significantly enhanced MIC50 for all the echinocandins (P<0.001). Resistance was mainly observed in strains of C. glabrata. In fact, while the resistance of C. albicans to echinocandins was limited to two strains, that of C. glabrata ranged between 7.32 % for micafungin and anidulafungin through to 8.89 % for caspofungin. As evidenced by Pfaller et al. [31] the mutation in the hot spot (HS) regions of the FKS gene that encodes the target enzyme (glycan synthase) for echinocandins may lead to MICs of anidulafungin, caspofungin and micafungin that are greater than the CBPs or ECVs for C. glabrata. However, these observations do not fully explain the increasing resistance rates in our hospital and, since we had no further data on antifungal use, it is difficult to draw any further conclusions. All these resistant strains were isolated in our study in the ICU settings, and are the topic of an ongoing study. In our opinion, this study suffers from at least two limitations: it is devoid of data concerning the mortality due to candidaemia, and it lacks data information concerning drug consumption during the study period. However, our study highlighted differences with other global and local studies concerning incidence, etiology and drug susceptibility, demonstrating that the integration of global-scale data with local epidemiology could be of high importance in the management of BSIs involving Candida spp. 
